Subscribe to RSS
DOI: 10.1055/s-0028-1092755
© Georg Thieme Verlag KG Stuttgart · New York
Plasma Lipids and High Density Lipoproteins during Oral Contraception with Different Combinations of Ethinyl Estradiol and Levonorgestrel
Publication History
Publication Date:
17 December 2008 (online)
![](https://www.thieme-connect.de/media/hmr/197907/lookinside/thumbnails/10.1055-s-0028-1092755-1.jpg)
Abstract
Seventyfive menstruating women seeking contraceptive advice were randomly allocated to treatment with combined oral contraceptives containing either ethinyl estradiol 50µg + levonorgestrel 250µg (50/250), ethinyl estradiol 30µg + levonorgestrel 150 µg (30/150) or ethinyl estradiol 50 µg + levonorgestrel 125 µg (50/125). The concentrations of cholesterol, triglycerides, phospholipids, high density lipoprotein (HDL)-cholesterol and HDL-phospholipids were determined after one, three and six months and compared to the mean of two determinations of the same parameters before medication.
Triglycerides increased by 18-42 per cent after 1-6 months of treatment with 50/125. The HDL-cholesterol and HDL-phospholipids were reduced by 10 per cent during 50/250 treatment. No other parameters showed any consistent alteration in any of the treatment groups.
Raised triglyceride concentration and/or decreased HDL concentration increases the risk for cardiovascular disease. It is therefore suggested that in order not to alter the HDL concentration a combined oral contraceptive agent should not contain more gestagen-androgen than corresponding to 125-150 µg of levonorgestrel. To avoid a rise of the triglyceride level the weight relation between levonorgestrel and ethinyl estradiol should be about 5:1.
Key words
Plasma Lipids - High Density Lipoproteins - Oral Contraception - Ethinyl Estradiol - Levonorgestrel